SAN DIEGO, April  06, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ:LPCN). The investigation focuses on Lipocine&#39;s executive officers and

LPCN

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel Investigates Lipocine Following Failed LPCN 1154 Trial

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, April  06, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ:LPCN). The investigation focuses on Lipocine&amp;#39;s executive officers and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel is investigating Lipocine Inc. after LPCN 1154 failed its Phase 3 trial, failing to meet the primary endpoint. This could lead to potential claims for investor losses under federal securities laws, impacting the company&#039;s stock performance and investor confidence going forward.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel is investigating potential claims against Lipocine.</li><li>LPCN 1154 failed Phase 3 trial for postpartum depression treatment.</li><li>The primary endpoint was not met, resulting in stock price decline.</li><li>Investors may have legal recourse for losses under federal securities laws.</li><li>Lipocine plans to conserve capital and review options post-trial failure.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Lipocine Inc. (LPCN)</strong>: The company&#039;s failure in clinical trials creates legal and financial risks.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This news fits under &#039;Legal&#039; as it involves a law firm&#039;s investigation into potential securities fraud concerning Lipocine&#039;s disclosures and trial outcomes, which could have significant implications for the company&#039;s stock value.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Failed trial results may lead to increased scrutiny from regulators.</li><li>Ongoing investigation could spark additional investor lawsuits.</li><li>Capital conservation measures may delay new product developments.</li><li>Investor sentiment could worsen, driving stock price further down.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>LPCN 1154 did not achieve statistically significant results in Phase 3 trial.</li><li>The primary endpoint was not met in the trial reported on April 2, 2026.</li><li>Lipocine&#039;s stock price declined following trial results announcement.</li><li>Johnson Fistel is a law firm specializing in securities fraud investigations.</li><li>Investors who suffered losses can potentially join the investigation.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting LPCN in the near term due to ongoing legal investigations.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, April  06, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LPCN">LPCN</a>). The investigation focuses on Lipocine's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased Lipocine securities?</strong><br></br>If you purchased Lipocine securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=M7HEgZpMv9gfYgw9594dckGwVKZl08mTFh_xKyTxrdB5FOOQ19G4tTQgKsOokRhy26ZjPcNgI2Yg1b7wLk_sEjTSt1h0vVvcdT8T3lHqXabrfuGuJf4BzpDpS-FJBUsV1gXC0BwuRuUKwqk2q9_9ENQ0_d6-emn-7dElcXA331I=" rel="nofollow" target="_blank">Click here to join the investigation</a>.<br></br>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.<br></br>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On April 2, 2026, Lipocine announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 for the treatment of postpartum depression. Among other things, the Company disclosed that LPCN 1154 "did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met."</p>  <p>The Company stated that it plans to preserve capital and evaluate all available options going forward. Following these disclosures, the price of Lipocine stock declined, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether Lipocine complied with the federal securities laws. If you suffered losses from your investment in Lipocine stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=xkhYDog3N0FsJo_IJX0-Obd7OWB-eYnnK3LVa02aOUf62bxozSi8hFgYhLCAhaUWiaqFPjHjyRP2aAWQYHGYqD_MhdSpp5Y_ewOKqpfA2ao=" rel="nofollow" target="_blank"><u>www.johnsonfistel.com</u></a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NDUwNiM3NTE5MDAyIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/Njg3ZjU3MzEtNDk5MC00MTZmLTlkOGMtMTliY2QzNjdjNDEwLTExOTMzNTgtMjAyNi0wNC0wNi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel is investigating Lipocine Inc. after LPCN 1154 failed its Phase 3 trial, failing to meet the primary endpoint. This could lead to potential claims for investor losses under federal securities laws, impacting the company's stock performance and investor confidence going forward.

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News